BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 27322684)

  • 1. PRAME expression and promoter hypomethylation in epithelial ovarian cancer.
    Zhang W; Barger CJ; Eng KH; Klinkebiel D; Link PA; Omilian A; Bshara W; Odunsi K; Karpf AR
    Oncotarget; 2016 Jul; 7(29):45352-45369. PubMed ID: 27322684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic activation of POTE genes in ovarian cancer.
    Sharma A; Albahrani M; Zhang W; Kufel CN; James SR; Odunsi K; Klinkebiel D; Karpf AR
    Epigenetics; 2019 Feb; 14(2):185-197. PubMed ID: 30764732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation.
    Guerrero K; Wang Z; Bachvarova M; Gregoire J; Renaud MC; Plante M; Bachvarov D
    Gynecol Oncol; 2012 Jun; 125(3):720-6. PubMed ID: 22446619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coordinated cancer germline antigen promoter and global DNA hypomethylation in ovarian cancer: association with the BORIS/CTCF expression ratio and advanced stage.
    Woloszynska-Read A; Zhang W; Yu J; Link PA; Mhawech-Fauceglia P; Collamat G; Akers SN; Ostler KR; Godley LA; Odunsi K; Karpf AR
    Clin Cancer Res; 2011 Apr; 17(8):2170-80. PubMed ID: 21296871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter hypermethylation influences the suppressive role of maternally expressed 3, a long non-coding RNA, in the development of epithelial ovarian cancer.
    Sheng X; Li J; Yang L; Chen Z; Zhao Q; Tan L; Zhou Y; Li J
    Oncol Rep; 2014 Jul; 32(1):277-85. PubMed ID: 24859196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-testis antigen expression is shared between epithelial ovarian cancer tumors.
    Garcia-Soto AE; Schreiber T; Strbo N; Ganjei-Azar P; Miao F; Koru-Sengul T; Simpkins F; Nieves-Neira W; Lucci J; Podack ER
    Gynecol Oncol; 2017 Jun; 145(3):413-419. PubMed ID: 28392126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation and nucleosome occupancy regulate the cancer germline antigen gene MAGEA11.
    James SR; Cedeno CD; Sharma A; Zhang W; Mohler JL; Odunsi K; Wilson EM; Karpf AR
    Epigenetics; 2013 Aug; 8(8):849-63. PubMed ID: 23839233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation.
    Sernbo S; Gustavsson E; Brennan DJ; Gallagher WM; Rexhepaj E; Rydnert F; Jirström K; Borrebaeck CA; Ek S
    BMC Cancer; 2011 Sep; 11():405. PubMed ID: 21943380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
    Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Taverna P; Karpf AR; Griffiths EA
    Epigenetics; 2015; 10(3):237-46. PubMed ID: 25793777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer.
    Link PA; Zhang W; Odunsi K; Karpf AR
    Cancer Immun; 2013; 13():6. PubMed ID: 23390377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic and expression analysis of TRAIL-R2 and BCL2: on the TRAIL to knowledge of apoptosis in ovarian tumors.
    Braga Lda C; Silva LM; Piedade JB; Traiman P; da Silva Filho AL
    Arch Gynecol Obstet; 2014 May; 289(5):1061-9. PubMed ID: 24190693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.
    Odunsi K; Matsuzaki J; James SR; Mhawech-Fauceglia P; Tsuji T; Miller A; Zhang W; Akers SN; Griffiths EA; Miliotto A; Beck A; Batt CA; Ritter G; Lele S; Gnjatic S; Karpf AR
    Cancer Immunol Res; 2014 Jan; 2(1):37-49. PubMed ID: 24535937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 16. Single CpG island methylation is not sufficient to maintain the silenced expression of CASPASE-8 apoptosis-related gene among women with epithelial ovarian cancer.
    Braga Lda C; Silva LM; Ramos AP; Piedade JB; Vidigal PV; Traiman P; da Silva Filho AL
    Biomed Pharmacother; 2014 Feb; 68(1):87-91. PubMed ID: 24412083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Upregulation of centrosomal protein 55 is associated with unfavorable prognosis and tumor invasion in epithelial ovarian carcinoma.
    Zhang W; Niu C; He W; Hou T; Sun X; Xu L; Zhang Y
    Tumour Biol; 2016 May; 37(5):6239-54. PubMed ID: 26615423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpression of trophoblast cell surface antigen 2 as an independent marker for a poor prognosis and as a potential therapeutic target in epithelial ovarian carcinoma.
    Xu N; Zhang Z; Zhu J; Xu L; Li Y; Duan L; Mao Y; Li H
    Int J Exp Pathol; 2016 Apr; 97(2):150-8. PubMed ID: 27127000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.
    de Leon M; Cardenas H; Vieth E; Emerson R; Segar M; Liu Y; Nephew K; Matei D
    Gynecol Oncol; 2016 Sep; 142(3):539-47. PubMed ID: 27374141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of discoidin domain receptor 1 (DDR1) via CpG methylation during EMT in epithelial ovarian cancer.
    Chung VY; Tan TZ; Huang RL; Lai HC; Huang RY
    Gene; 2017 Nov; 635():9-15. PubMed ID: 28887161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.